Cyclosporine — I have cholinergic-induced urticaria and have not responded to standard treatment — Xolair

Reading time: 11 min
WhatsApp ↗
Medical Encyclopedia · Allergy and Clinical Immunology

Cyclosporine — I have cholinergic-induced urticaria and have not responded to standard treatment — Xolair

Clinical Summary and Overview

To clearly understand the clinical aspects involved in Induced Urticaria This is an essential step for those seeking diagnostic certainty, lasting symptom relief, and prevention of complications. In the daily practice of Allergology and Clinical Immunology, questions related to... "Cyclosporine — I have cholinergic-induced urticaria and have not responded to standard treatment — Xolair" Allergy-free conditions are common among patients and their families. The goal of this page in the Brazil Allergy-Free Encyclopedia is to present a complete, accessible, and evidence-based medical analysis, detailing causes, immunological mechanisms, and safe practices.

✔ Medical content reviewed and validated by the founding clinical staff of the Brazil Without Allergies Project

Dr. Marcello Bossois (CRM-RJ 52.73214-1) · Dr. Patricia Schlinkert (CRM/RJ 5274541-3) — more than 30 years of history in Allergy and Immunology, with units in Rio de Janeiro, São Paulo and Paraná. Last reviewed: November 2026.

Cyclosporine — I have cholinergic-induced urticaria and have not responded to standard treatment — Xolair

The Use of Cyclosporine and Alternatives in the Treatment of Cholinergic-Induced Urticaria

Cholinergic-induced urticaria is a challenging dermatological condition, especially when the patient does not respond satisfactorily to standard treatment with antihistamines. In these difficult-to-control cases, medical guidelines often contemplate the use of immunomodulatory and immunobiological drugs. Cyclosporine, for example, is traditionally used as an advanced resource in the management of severe chronic urticaria.

However, the therapeutic choice requires a rigorous medical evaluation, considering that cyclosporine acts as a systemic immunosuppressant. This characteristic demands heightened caution, particularly in scenarios of systemic viral infections—such as the historical context of the COVID-19 pandemic—a time when specialists carefully weigh the risks and benefits of therapies that alter the cellular immune response.

On the other hand, monoclonal antibodies, such as omalizumab (Xolair), represent significant advances in the treatment of difficult-to-control urticaria. Compared to classic immunosuppressants, immunobiologics usually offer a different safety profile, as they act in a targeted manner on specific allergic cascades without causing the broad immunosuppression typical of cyclosporine. For this reason, contemporary medical practice frequently re-evaluates the sequence of therapeutic escalation, prioritizing options with less systemic impact whenever clinically indicated.

Access to High-Cost Treatments

Access to high-cost medications for the treatment of severe and refractory allergic diseases involves specific regulatory and legal pathways. Both beneficiaries of supplementary health plans and users of the Unified Health System (SUS) have legally guaranteed rights to obtain essential treatments, provided there is a medical indication based on a detailed clinical report.

  • Health Plans: If the health plan denies coverage, the patient can first appeal to the National Supplementary Health Agency (ANS) for mediation and, if necessary, seek assistance from the judiciary.
  • Unified Health System (SUS): The Brazilian Unified Health System (SUS) has its own procedures for dispensing specialized medications. When the administrative process is not handled with the necessary speed, the judicial process also presents itself as a legal instrument to ensure the right to health.

It is essential that patients with refractory cholinergic-induced urticaria maintain close follow-up with a specialist in Allergy and Immunology. Only a thorough, individualized assessment can define the safest and most effective therapeutic strategy for controlling symptoms and improving quality of life. This content is strictly educational and informative in nature and does not, under any circumstances, replace consultation, diagnosis, and specialized medical prescription from the Brazil Without Allergies Project.

Developments in Evidence-Based Medicine: Pharmacology of Immunobiologics and Precision Medicine

In Evidence-Based Medicine, the indication of immunobiological agents (monoclonal antibodies and receptor fusion proteins) It is based on the patient's inflammatory endotyping. Selective blocking of molecular targets — such as the neutralization of free IgE by omalizumab (in severe allergic asthma and chronic spontaneous urticaria refractory to quadrupled-dose H1 antihistamines), the dual inhibition of IL-4 and IL-13 interleukin signaling by dupilumab (In moderate to severe atopic dermatitis, eosinophilic/Th2 asthma, and chronic rhinosinusitis with nasal polyposis), the blockade of the TSLP epithelial alarm by tezepelumab or blocking the IL-5/IL-5R pathway — allows control of the inflammatory cascade at its cellular origin, reducing exacerbations and sparing the patient from the adverse metabolic, endocrine, and cardiovascular effects of prolonged systemic corticosteroid use.

💎 Diamond Plan — Peaceful skin, free from constant itching and sleepless flare-ups. Speak with an Allergy and Immunology specialist via teleconsultation, from anywhere in Brazil. Schedule a teleconsultation →

Note: Subject to prior medical evaluation (in person or via telemetry/telemedicine). Immunotherapy uses allergen-specific vaccines, which requires a prescription from the attending physician and must be administered under direct medical supervision.

Pathophysiology of Urticaria and Angioedema: Safe Diagnosis and Management

Mast Cell Activation, Histamine, and the Bradykinin Pathway

Urticaria is characterized by the sudden appearance of hives (intensely itchy, erythematous and edematous papules that are fleeting and disappear in less than 24 hours in the same spot without leaving a scar), and may be accompanied by angioedema in the deeper layers of the dermis and submucosa. In acute cases (lasting less than six weeks), viral infections, foods, and medications are among the classic triggers; while in chronic spontaneous urticaria or induced urticaria (dermographic, cholinergic due to sweat/heat, cold, or delayed pressure), autoimmune mechanisms or mast cell hyperreactivity play a central role.

Therapeutic Escalation without Overuse of Corticosteroids

International guidelines recommend second-generation (non-sedating) H1 antihistamines at optimized doses under medical supervision as first-line treatment, reserving anti-IgE monoclonal antibodies (such as omalizumab) for refractory chronic cases and avoiding repeated cycles of systemic corticosteroids that cause a rebound effect. The investigation with allergy test and specialized skin assessment allows for the exclusion of hidden triggers and the alignment of strategies such as, when atopy coexists, allergy vaccine.

Selective Blockade of Cytokines (IL-4, IL-5, IL-13, TSLP) and Immunoglobulin E

Choosing the ideal immunobiological agent requires rigorous phenotyping and endotyping by a specialist physician, evaluating blood biomarkers (peripheral eosinophil count, serum levels of total IgE and exhaled fraction of nitric oxide) and coexisting comorbidities, such as severe asthma, nasal polyposis, refractory chronic spontaneous urticaria, and moderate to severe atopic dermatitis. Subcutaneous applications follow a regular schedule under safe clinical supervision.

Immediate Reactions, Delayed Drug Reactions, and Risks of Self-Medication

Drug hypersensitivity reactions encompass distinct immunological and pharmacological mechanisms: from immediate reactions (up to one to six hours after dosing, manifested by urticaria, labial or palpebral angioedema, bronchospasm, and anaphylaxis, common with COX-1 inhibitor analgesics and beta-lactams) to delayed drug eruptions mediated by T cells, such as maculopapular rashes and DRESS syndrome — a systemic condition that arises weeks after the start of anticonvulsants, sulfones, or allopurinol, presenting with fever, lymphadenomegaly, eosinophilia, and the need for immediate discontinuation under hospital supervision.

Vaccine Mechanisms, Excipients, and Assessment of Immune Competence

In assessing the competence of the immune system—whether in recurrent infections, laboratory alterations in immunoglobulins (IgG, IgA, IgM, IgE), or in people living with HIV under monitoring of CD4 T lymphocyte counts—a careful distinction is made between the use of inactivated/subunit vaccines (widely safe even in immunocompromised individuals) and live attenuated vaccines, whose indication depends on the degree of preservation of cellular immunity. Furthermore, patients undergoing allergy immunotherapy can maintain their vaccination schedule, respecting only small operational intervals as directed by the medical team.

Diamond Plan: Specialized Allergy Treatment Wherever You Are

SIGNATURE
DIAMOND

Allergy-Free Brazil

THE FUTURE OF TREATMENT

💎

  • Allergy and immunostimulant vaccines included.
  • Easy access (upon request)
  • Nationwide coverage — all of Brazil

brasilsemalergia.online

We know that, for many families, allergy treatment faces two concrete obstacles: high cost of allergy vaccines and the distance to a specialized centerThe Diamond Plan It was created precisely to remove these barriers, combining teleconsultation with specialists and easy access to immunotherapy throughout the country. For peaceful skin, free from constant itching and sleepless nights due to flare-ups.

Why do patients across Brazil choose the Diamond Plan?

  • Teleconsultation with a specialist In Allergy and Immunology, without queues and without long commutes — ideal for those who live far from large cities.
  • easy access to Immunotherapy (including allergy vaccines and immunostimulants) — indicated for the treatment of allergic rhinitis, asthma, bronchitis, atopic dermatitis, insect/mosquito bite allergy (prurigo strophulus), recurrent candidiasis, and for increasing immunity in selected patients — capable of modifying the natural course of allergic disease, always through consultation and individualized prescription.
  • A more accessible route For those facing the high cost of allergy vaccines, this plan offers support for continuity of treatment.
  • Continuous monitoring based on clinical evolution, with adjustments to treatment throughout the entire therapeutic cycle.
  • National coverage, backed by a consolidated physical network and a founding clinical team with over three decades of experience.

More than 30 years caring for people with allergies.

Founded and run by Dr. Marcello Bossois (CRM-RJ 52.73214-1) and by Dr. Patrícia Schlinkert (CRM/RJ 5274541-3)The Brazil Without Allergies Project adds... more than 30 years of history and more than 450,000 free services, with physical presence at Rio de Janeiro, São Paulo and Paraná, one mobile clinic bus that brings testing and consultations to communities with limited access to specialized care and a platform of telemedicine which connects patients from all states to the same standard of care.

START TODAY

Your expert consultation is just a click away.

I want to join the Diamond Plan.Schedule a teleconsultation

Official telemedicine environment: brasilsemalergia.online

Do you prefer to be served in person?

Our clinical units They conduct consultations, allergy tests, and immunotherapy follow-up with doctors in person:

Schedule your in-person appointment. Or check the mobile bus schedule through the customer service center on WhatsApp. (21) 99954-5632.

The indication for immunotherapy, and for any treatment, depends on an individual medical evaluation. This content is for informational purposes only and does not replace consultation with a specialist.

Note: Subject to prior medical evaluation (in person or via telemetry/telemedicine). Immunotherapy uses allergen-specific vaccines, which requires a prescription from the attending physician and must be administered under direct medical supervision.

Conclusion and Summary of Guidelines

In summary, the appropriate approach to Induced Urticaria It requires a clear understanding of the immunological mechanisms involved, accurate etiological diagnosis, and individualized medical follow-up. Avoid self-medication and investigate the root cause of symptoms—relying on specialized resources and reliable guidance such as... rhinitis treatment When clinically relevant, it is the safest way to manage crises, prevent complications, and ensure sustainable quality of life.

Scientific references and authoritative sources

The guidelines on this page follow the guidelines and literature of leading international Allergy and Immunology institutions. For further information: